[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fjAgImv0R0l-s6dvBAgSG-gMRjhLnK3Sq8mVCpev7QB4":8,"$f5uh_bO9uLWClEGV7Kql4aZ6ZQao7wHHYtEsDTX_FVeE":55,"$fTvEq9g-vxr2FVK2bTpdndIJsRFGu3h2YEExNn1tB1oI":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},51902,870211,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//asknO5BON4ILmaGySngB678AjuK0nT7z.png","杜慧敏","合肥佰惠医院","内科","住院医师",92,0,"肺癌四期综合治疗中的EGFR靶向药实用用药指南","","https://ystcdn.venuertc.com/venue/AI/e8b2564a-3e24-4956-8e84-4c02b5468dac.jpg","\u003Cdiv class=\"egfr-med-guide-content\">\n\n  \u003Ch1 id=\"material_title\" class=\"egfr-med-guide-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">\n    肺癌四期综合治疗中的EGFR靶向药实用用药指南\n  \u003C/h1>\n\n  \u003Cdiv class=\"egfr-section egfr-section-intro\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">💊\u003C/span>\n    \u003C/div>\n    \u003Cp class=\"egfr-intro-text\">\n      说到EGFR靶向药，很多人在肺部肿瘤的治疗过程中可能听医生提起过，比如吉非替尼、厄洛替尼等。这类药品以“分子精准打击”为特点，已经成为综合治疗的中坚力量。但要让药效发挥最大、用得安心，还得掌握不少细节。本文将详细讲解EGFR靶向药使用中的关键细节——包括成分、剂型、服用时机、相互作用、不良反应等共7大要点，帮助大家更明白每一步怎么用、需要注意什么，尽量减少风险。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 1. 成分、剂型与规格一览 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">🔬\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 成分、剂型与规格一览\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>主流EGFR靶向药品：\u003C/b>吉非替尼（Gefitinib）、厄洛替尼（Erlotinib）、奥希替尼（Osimertinib）是临床常用代表。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>剂型：\u003C/b>多为片剂或薄膜衣片，便于口服。有些为胶囊剂型。如奥希替尼为片剂，常见剂量为80mg/片。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>规格：\u003C/b>\n        \u003Cul>\n          \u003Cli>吉非替尼：250mg/片\u003C/li>\n          \u003Cli>厄洛替尼：150mg/片\u003C/li>\n          \u003Cli>奥希替尼：80mg/片\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b>使用药品前务必看清楚包装上的成分、剂型和规格。不同药剂量不能混用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>提醒：\u003C/b>不要自行更改药品或者替换成分，必须由专业医师指导下更换。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-info\">EGFR靶向药都属于处方药，需医生指导下获取。\u003C/div>\n  \u003C/div>\n\n  \u003C!-- 2. 作用机制简单说清 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">🧬\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药品作用机制简易说明\u003C/h2>\n    \u003Cp>\n      EGFR靶向药的核心思路是“精准阻断”——药物会与细胞表面的表皮生长因子受体（EGFR）结合，阻止其激活和下游信号转导。这样能有效削弱肿瘤细胞的生存和分裂能力，使靶向适合基因突变的细胞生长受限。\n      \u003Cbr>\n      \u003Cb>举例：\u003C/b>吉非替尼、厄洛替尼、奥希替尼都属于酪氨酸激酶抑制剂（TKI），通过不可逆或可逆结合方式，延缓或阻止异常信号传递。\n    \u003C/p>\n    \u003Cdiv class=\"egfr-tip egfr-tip-warning\">\n      这种药物仅在EGFR突变的肿瘤患者中有效，对无显著EGFR突变的人群意义有限。\n    \u003C/div>\n    \u003Cdiv class=\"egfr-citation\">参考文献：Mok, T. S., Wu, Y-L., & Thongprasert, S. et al. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. \u003Ci>New England Journal of Medicine\u003C/i>, 361(10), 947-957.\u003C/div>\n  \u003C/div>\n\n  \u003C!-- 3. 服用时间和方式要点 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">⏰\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 服用时间和方法有哪些讲究\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>吉非替尼：\u003C/b> 推荐每日一次，每次250mg，固定时间（建议每次与上一餐间隔2小时以上），以一杯温水送服。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>厄洛替尼：\u003C/b> 最好空腹服用（餐前至少1小时或餐后2小时），一次150mg，一天一次。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>奥希替尼：\u003C/b> 通常每日一次，餐前餐后均可，80mg为常规起始剂量。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>服药方法：\u003C/b>整片吞服，勿掰碎、嚼碎或研粉。需要时用温水帮助吞咽（避免茶、奶等）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>正确做法：\u003C/b>尽量每天同一时段用药，把药品和水准备齐全，避免因忘服影响疗效。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-important\">\n      如出现忘服，记得补服，不宜同时服用两倍剂量。超过12小时后建议跳过，继续下一次正常剂量。\n    \u003C/div>\n    \u003Cdiv class=\"egfr-citation\">参考文献：Soria, J. C., Ohe, Y., Vansteenkiste, J. et al. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 378(2), 113-125.\u003C/div>\n  \u003C/div>\n\n  \u003C!-- 4. 相互作用与用药搭配注意点 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">⚠️\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用与用药搭配\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>胃酸抑制药影响：\u003C/b>质子泵抑制剂、H2受体拮抗剂等抑酸药会降低吉非替尼和厄洛替尼在体内的吸收，减少疗效。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>与其他药物的相互作用：\u003C/b>\n        \u003Cul>\n          \u003Cli>吉非替尼、厄洛替尼均经肝脏CYP3A4代谢，避免与强诱导剂（如利福平）、抑制剂（如酮康唑等）同服。\u003C/li>\n          \u003Cli>奥希替尼不推荐与强CYP3A抑制剂/诱导剂一起使用，否则药物浓度可能变化。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>营养补充剂与草药：\u003C/b>部分补充剂或草药（如葡萄柚制品、圣约翰草）会影响代谢酶活性，需提前咨询医师。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-warning\">\n      用药前请主动报备全部正在服用的药品、维生素和草药，防止不必要的相互作用影响。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 5. 老年和特殊人群用药要点 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">👵\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 老年与特殊人群用药\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>老年人：\u003C/b>\n        通常不需因年龄额外调整剂量，但需评估肝肾功能（肝肾功能障碍时可能需下调剂量）。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>肝肾功能减退：\u003C/b>\n        中重度肝损伤患者需谨慎，具体方案由医生权衡风险。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>女性与孕期：\u003C/b>\n        孕妇禁止使用，哺乳期应暂停喂养或停药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>儿童和青少年：\u003C/b>\n        EGFR靶向药尚未明确推荐儿童适应症，不建议自行使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>实际案例：\u003C/b> 一位60岁女性用吉非替尼期间出现轻微食欲减退，经调整饮食与定期复查，安全坚持治疗。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-important\">\n      特殊人群用药方案不能照搬成人标准，药剂调整需经过专业评估。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 6. 常见不良反应及应对 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">😷\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及处理技巧\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>最常见副作用：\u003C/b>皮疹、腹泻、口腔溃疡、轻度恶心、食欲减退等。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>皮疹：\u003C/b>如出现皮肤瘙痒、红疹，可选用润肤剂，严重时请及时与医生联系调整用药。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>腹泻：\u003C/b>轻度时多饮水，如便次增加明显则需就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>严重不良反应：\u003C/b>如持续高热、呼吸困难、黄疸、严重脱水等，属紧急情况，应马上就医。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>处理原则：\u003C/b>轻度反应可咨询医生调整支持疗法，重度反应勿自行处理，需停药评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>数据表明：\u003C/b>以奥希替尼为例，皮疹发生率约58%，腹泻约48%。详见药品说明书。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>实际用药经验：\u003C/b>有位患者服用厄洛替尼后出现轻度皮疹，通过短期调整辅助药物后顺利继续治疗。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-info\">\n      若出现以上不适，保持用药记录，及时告知医疗人员有助于更好处理。\n    \u003C/div>\n    \u003Cdiv class=\"egfr-citation\">参考文献：Yang, J. C. H., Wu, Y. L., Schuler, M., et al. (2015). Afatinib versus gefitinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. \u003Ci>Lancet Oncology\u003C/i>, 16(9), 965-973.\u003C/div>\n  \u003C/div>\n\n  \u003C!-- 7. 储存方法与有效期管理 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">🌡️\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存方法与有效期管理\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>储存温度：\u003C/b>常温保存（一般15-30°C），避免高温潮湿和直射阳光。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>开封后管理：\u003C/b>保持药品干燥，避免与日常食品、饮料存放在一起，不要放在浴室等潮湿环境。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>有效期：\u003C/b>药品过期不得服用。部分药物开封后有特定时限，见说明书细则。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>处理方法：\u003C/b>过期或不用的药品应交由药房或医疗点回收处理，禁倒入下水道。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-warning\">\n      切勿把药品混在他人药盒里，防止误服或混用。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 8. 日常管理与生活辅助建议 -->\n  \u003Cdiv class=\"egfr-section\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">🏡\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 日常管理与健康小提示\u003C/h2>\n    \u003Cul class=\"egfr-list\">\n      \u003Cli>\n        \u003Cb>药盒分装：\u003C/b>建议用专门药盒分装一周用药，便于随手提醒，不易忘记。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>水分补充：\u003C/b>服用TKI药物易出现口腔干燥、皮肤干等副作用，每天保持足量饮水。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>饮食注意：\u003C/b>荤素搭配，多吃新鲜蔬果，减少油腻刺激食物。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>身体监测：\u003C/b>每月定期按医师要求验血、肝肾功能或定期复查。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>家庭成员关注：\u003C/b>配合帮助患者监督用药及生活管理，避免遗漏。\n      \u003C/li>\n      \u003Cli>\n        \u003Cb>实际用药案例：\u003C/b>临床上有患者调整饮食与作息后，皮肤副作用明显减轻，坚持完成疗程。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"egfr-tip egfr-tip-info\">\n      多关注身体的小变化，必要时随时向医生咨询，不要擅自终止或加量用药。\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 总结警示 -->\n  \u003Cdiv class=\"egfr-section egfr-section-summary\">\n    \u003Cdiv class=\"egfr-section-bg\">\n      \u003Cspan class=\"egfr-emoji\">✅\u003C/span>\n    \u003C/div>\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结与用药安全叮咛\u003C/h2>\n    \u003Cp>\n      EGFR靶向药治疗是分子精准治疗的典型代表，合理选择、规范用药、重视用药细节，能明显降低副作用风险、提升药效。\u003Cbr>\n      \u003Cspan class=\"egfr-highlight\">最重要的两点：\u003C/span>一、吃药前后严格按说明书及医嘱操作；二、对不明不适或疑问，及时关注和反馈，不擅自停用。安全用药，家人支持也同样重要。祝大家用药无忧，健康每一天。\n    \u003C/p>\n  \u003C/div>\n\n  \u003C!-- 文献区 -->\n  \u003Cdiv class=\"egfr-section egfr-section-refs\">\n    \u003Ch2 class=\"egfr-section-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献\u003C/h2>\n    \u003Col class=\"egfr-refs-list\">\n      \u003Cli>\n        Mok, T. S., Wu, Y-L., & Thongprasert, S., et al. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. \u003Ci>New England Journal of Medicine\u003C/i>, 361(10), 947-957.\n      \u003C/li>\n      \u003Cli>\n        Soria, J. C., Ohe, Y., Vansteenkiste, J., et al. (2018). Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 378(2), 113-125.\n      \u003C/li>\n      \u003Cli>\n        Yang, J. C. H., Wu, Y. L., Schuler, M., et al. (2015). Afatinib versus gefitinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. \u003Ci>Lancet Oncology\u003C/i>, 16(9), 965-973.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\n\u003C/div>\n\n\u003Cstyle>\n.egfr-med-guide-content {\n  font-family: 'Helvetica Neue', Helvetica, Arial, 'PingFang SC', 'Microsoft YaHei', sans-serif;\n  max-width: 820px;\n  margin: 38px auto 36px auto;\n  background: #fafbfd;\n  padding: 36px 34px 28px 34px;\n  border-radius: 14px;\n  box-shadow: 0 8px 24px 0 rgba(43, 67, 105, 0.06), 0 1.5px 2px 0 rgba(33, 65, 129, 0.03);\n}\n\n.egfr-med-guide-title {\n  font-size: 2.1em;\n  font-weight: 700;\n  margin-bottom: 16px;\n  text-align: center;\n  letter-spacing: 1px;\n  color: #33496d;\n  padding-bottom: 13px;\n  border-bottom: 2px solid #ecedee;\n}\n\n.egfr-section {\n  margin-bottom: 38px;\n  position: relative;\n  background: #f5f9fc;\n  padding: 26px 26px 22px 26px;\n  border-radius: 10px;\n  box-shadow: 0 2px 8px 0 rgba(212, 216, 232, 0.07);\n}\n\n.egfr-section-bg {\n  background: linear-gradient(97deg, #eef4fb 40%, #f6f6f9 100%);\n  border-radius: 8px;\n  padding: 6px 0 5px 12px;\n  margin-bottom: 8px;\n  display: flex;\n  align-items: center;\n  min-height: 30px;\n}\n\n.egfr-section .egfr-emoji {\n  font-size: 1.5em;\n  display: inline-block;\n  margin-right: 10px;\n  vertical-align: middle;\n}\n\n.egfr-section-title {\n  font-size: 1.25em;\n  color: #2e4a6b;\n  font-weight: 650;\n  margin-top: 7px;\n  margin-bottom: 14px;\n  text-shadow: 0 0.5px 0 #f0f2f5;\n}\n\n.egfr-list {\n  padding-left: 1.6em;\n  line-height: 1.85;\n  font-size: 1.02em;\n  margin-bottom: 9px;\n}\n\n.egfr-list ul {\n  padding-left: 1.2em;\n  margin: 4px 0 2px 0;\n}\n\n.egfr-tip {\n  margin: 16px 0 8px 0;\n  padding: 12px 18px;\n  border-radius: 7px;\n  font-size: 1em;\n  font-weight: 520;\n  background: linear-gradient(96deg, #e7f6ff 60%, #f8fcff 100%);\n}\n\n.egfr-tip-info {\n  border-left: 6px solid #53add1;\n  color: #1b5680;\n}\n\n.egfr-tip-warning {\n  border-left: 6px solid #eaa45e;\n  background: linear-gradient(93deg, #fdf7e5 72%, #fcfbf5 100%);\n  color: #95622c;\n}\n\n.egfr-tip-important {\n  border-left: 6px solid #6ecb94;\n  background: linear-gradient(93deg, #d1faea 80%, #f5fcf5 100%);\n  color: #186d46;\n}\n\n.egfr-highlight {\n  background: linear-gradient(90deg,#fbe5c8 90%,#fff8f1 100%);\n  border-radius: 5px;\n  padding: 3px 9px;\n  font-weight: bold;\n  color: #a66a18;\n  margin-right: 5px;\n}\n\n.egfr-intro-text {\n  font-size: 1.17em;\n  color: #40648f;\n  margin: 8px 1px 11px 1px;\n  line-height: 1.7;\n}\n\n.egfr-citation {\n  font-size: 0.97em;\n  color: #8395a7;\n  margin: 14px 8px 2px 0;\n}\n.egfr-section-summary {\n  background: linear-gradient(95deg, #f6efe3 79%, #fbfaf5 100%);\n  border: 1.8px dotted #fbd5a4;\n}\n.egfr-refs-list {\n  font-size: 0.96em;\n  line-height: 1.8;\n  color: #4a6695;\n  padding-left: 1.6em;\n}\n.egfr-section-refs{\n  background: #f3f7fb;\n}\n@media (max-width: 700px) {\n  .egfr-med-guide-content {\n    padding: 16px 5vw 14px 6vw;\n    font-size: 1.05em;\n  }\n  .egfr-section {\n    padding: 16px 7px 14px 7px;\n    margin-bottom: 21px;\n  }\n  .egfr-section-title {\n    font-size: 1.13em;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"egfr-med-guide-content\">\n\n  \u003Ch1 id=\"material_title\" class=\"egfr-med-guide-title\" style=\"",422,"2025-07-24 10:29:51","EGFR靶向药, 肺癌, 吉非替尼, 厄洛替尼, 奥希替尼, 用药指南, 不良反应, 作用机制","本指南详细解析EGFR靶向药的使用要点，涵盖药物成分、服用方法、常见不良反应等，助您安全、有效治疗肺癌，享受健康生活。","2025-07-26 17:14:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]